Amgen
Decode Study Identifies Proteomic Predictors of All-Cause Mortality
Using Somalogic's SomaScan to analyze nearly 23,000 subjects, the researchers identified signatures indicating high and low risks of death within 10 years.
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Long-Read Sequencing Characterizes Structural Variants in Icelandic Population
By extrapolating from long-read genome sequences from 3,622 Icelanders, researchers profiled SV alleles and associated traits or conditions in the broader population.
Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC
As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status.
Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.